Hims & Hers Shares Rebound Following Regulatory Setback

Unexpected Recovery After Initial Plunge

The stock of telehealth company Hims & Hers Health, Inc. experienced a period of significant volatility after receiving a formal warning from the U.S. Food and Drug Administration (FDA). Despite an initial sharp sell-off, the equity demonstrated notable resilience, staging a partial recovery that has left market participants divided on its near-term prospects.

Investor sentiment soured dramatically on September 16 when the FDA’s warning letter became public knowledge. The announcement triggered an immediate sell-off, sending shares down by as much as 8% during the trading session. The decline reflected mounting concerns over potential legal repercussions and lasting damage to the company’s brand reputation.